erlotinib hydrochloride has been researched along with Retinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, LS; Marmor, MF; Neal, JW; Sequist, LV; Wakelee, HA | 1 |
| Anand-Apte, B; Blobel, CP; Chan, RV; Chiang, MF; Farage, E; Glomski, K; Hewing, NJ; Khokha, R; Swendeman, S; Vermaat, J; Weskamp, G | 1 |
1 trial(s) available for erlotinib hydrochloride and Retinal Diseases
| Article | Year |
|---|---|
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Electroretinography; Erlotinib Hydrochloride; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lung Neoplasms; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Field Tests; Visual Fields | 2015 |
1 other study(ies) available for erlotinib hydrochloride and Retinal Diseases
| Article | Year |
|---|---|
Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Intravitreal Injections; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Oxygen; Protein Kinase Inhibitors; Quinazolines; Retinal Diseases; Signal Transduction; Tissue Inhibitor of Metalloproteinase-3 | 2013 |